Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing…
News
2015/03/17 – Creation of a joint Inserm-Quantum Genomics laboratory at the Collège de France backed by the French National Agency for Research (ANR)
Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing…
2015/03/03 : First patients recruited for Phase IIa trial of drug candidate QGC001
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Quantum Genomics reports total capital increase after stabilization period: €12.9 million
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Remarkable uptake in Quantum Genomics IPO:1 €11.2 million raised
Quantum Genomics (Alternext – FR0011648971 – ALQGC) announces the great success of its Initial Public…
Quantum Genomics is launching a public equity offering on Alternext Paris, above all to fund the phase IIa clinical trials of its antihypertensive drug candidate QGC001
Quantum Genomics (Alternext – FR0011648971 – ALQGC) announces the launch of a public equity offering…
2015/01/12 – Quantum Genomics at J.P. Morgan 34th annual healthcare conference
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Catherine Llorens-Cortes receives the 2014 Galien France pharmaceutical research award for her work on the key role of angiotensin III at brain level in the control of blood pressure
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Quantum Genomics receives a 3 M€ financing
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Quantum Genomics announces the appointment of Dr Olivier Madonna as Chief Medical Officer
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…